Literature DB >> 12376086

Treatment of multiple sclerosis with lofepramine, L-phenylalanine and vitamin B(12): mechanism of action and clinical importance: roles of the locus coeruleus and central noradrenergic systems.

C Loder, J Allawi, D F Horrobin.   

Abstract

In a randomized, placebo-controlled double-blind trial a combination of lofepramine, phenylalanine and vitamin B(12) was found to be effective in relieving the symptoms of multiple sclerosis (MS). The effect occurred within 2-4 weeks, and improved all types of symptoms in all types of MS. The combination was also effective in relieving symptoms in patients with chronic pain and chronic fatigue. We hypothesize that the action of this combined therapy may relate to activation of the noradrenergic locus coeruleus/lateral tegmentum (LC/LT) system which has the potential to influence the functioning of large areas of the brain and spinal cord.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12376086     DOI: 10.1016/s0306-9877(02)00261-x

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  11 in total

1.  Urinary and Plasma Metabolomics Identify the Distinct Metabolic Profile of Disease State in Chronic Mouse Model of Multiple Sclerosis.

Authors:  J Singh; M Cerghet; L M Poisson; I Datta; K Labuzek; H Suhail; R Rattan; Shailendra Giri
Journal:  J Neuroimmune Pharmacol       Date:  2018-10-12       Impact factor: 4.147

2.  Increasing CNS noradrenaline reduces EAE severity.

Authors:  Maria Vittoria Simonini; Paul E Polak; Anthony Sharp; Susan McGuire; Elena Galea; Douglas L Feinstein
Journal:  J Neuroimmune Pharmacol       Date:  2009-12-04       Impact factor: 4.147

Review 3.  A mechanism-based classification of pain in multiple sclerosis.

Authors:  A Truini; P Barbanti; C Pozzilli; G Cruccu
Journal:  J Neurol       Date:  2012-07-04       Impact factor: 4.849

4.  Dietary interventions for multiple sclerosis-related outcomes.

Authors:  Natalie E Parks; Caitlin S Jackson-Tarlton; Laura Vacchi; Roah Merdad; Bradley C Johnston
Journal:  Cochrane Database Syst Rev       Date:  2020-05-19

5.  Fatigue in Multiple Sclerosis: Assessing Pontine Involvement Using Proton MR Spectroscopic Imaging.

Authors:  Wan Hazlin Zaini; Fabrizio Giuliani; Christian Beaulieu; Sanjay Kalra; Christopher Hanstock
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

6.  Disease Type- and Status-Specific Alteration of CSF Metabolome Coordinated with Clinical Parameters in Inflammatory Demyelinating Diseases of CNS.

Authors:  Soo Jin Park; In Hye Jeong; Byung Soo Kong; Jung-Eun Lee; Kyoung Heon Kim; Do Yup Lee; Ho Jin Kim
Journal:  PLoS One       Date:  2016-11-17       Impact factor: 3.240

7.  Role of catalpol in ameliorating the pathogenesis of experimental autoimmune encephalomyelitis by increasing the level of noradrenaline in the locus coeruleus.

Authors:  Qian Li; Tao Yang; An-Chen Guo; Yong-Ping Fan
Journal:  Mol Med Rep       Date:  2018-01-05       Impact factor: 2.952

Review 8.  Multiple Immune-Inflammatory and Oxidative and Nitrosative Stress Pathways Explain the Frequent Presence of Depression in Multiple Sclerosis.

Authors:  Gerwyn Morris; Edna Maria Vissoci Reiche; Andrea Murru; André F Carvalho; Michael Maes; Michael Berk; Basant K Puri
Journal:  Mol Neurobiol       Date:  2018-01-02       Impact factor: 5.590

9.  Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance.

Authors:  Matteo Martino; Giulio Rocchi; Andrea Escelsior; Michele Fornaro
Journal:  Curr Neuropharmacol       Date:  2012-06       Impact factor: 7.363

10.  Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid.

Authors:  Norbert W Lutz; Angèle Viola; Irina Malikova; Sylviane Confort-Gouny; Bertrand Audoin; Jean-Philippe Ranjeva; Jean Pelletier; Patrick J Cozzone
Journal:  PLoS One       Date:  2007-07-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.